Levadex has peak annual sales potential of $500M, according to AGN’s CC today; all of this comes from the US and Canada. The addressable patient pool is about 10x that of Botox for chronic migraine.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”